Évaluation de la sécurité et de la tolérabilité de doses uniques croissantes de NNC 0113-0217 administrées par voie sous-cutanée chez des sujets masculins en bonne santé

This clinical trial focuses on a drug called NNC 0113-0217. The main goal is to test how safe and well-tolerated this drug is when given as a single dose under the skin to healthy male participants. The trial takes place in Europe and aims to find the highest dose that can be given without causing unacceptable side effects, also known as the Maximum Tolerated Dose (MTD). This study is important as it helps to understand the safety profile of NNC 0113-0217, which is a crucial step in developing new treatments. During the trial, participants receive either NNC 0113-0217 or a placebo, a substance that looks like the drug but contains no active ingredients. This is a 'double-blind' trial, meaning neither the participants nor the researchers know who receives the drug or the placebo. The study measures the number of adverse events or side effects to evaluate the safety of the drug. As this is a phase 1 trial, it is one of the first times the drug is tested in humans, with a primary focus on safety.